WORCESTER, Mass., Sept. 4, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, will sponsor an international diabetes symposium in Rome, Italy as an adjunct to the 44th Annual Meeting of the European Association for the Study of Diabetes taking place in Rome from September 6-11, 2008.
The symposium, titled New Paradigms in the Management of Diabetes, will commence at 3 p.m. CEST on September 6, 2008 at Roma Eventi, Via Alibert 5/a - Piazza di Spagna. The program will feature speakers from University Campus Bio-Medico (Rome) and the Institute of Endocrinology IEMYR (Quito, Ecuador). Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs, and Dr. Jaime Davidson, the Company's Medical Director, will also address the gathering.
Topics to be canvassed include the epidemic aspects of diabetes, the International Diabetes Federation's new guidelines for post-prandial glucose, alternative methods for the delivery of prandial insulin, and the management of tight glycemic control. The specific presentations will be as follows:
* Opening remarks by Professor Paolo Pozzilli, University Campus Bio-Medico * Epidemiology of Diabetes, the New Epidemic by Dr. Nicola Napoli, University Campus Bio-Medico * New International Diabetes Federation Guidelines on Post-Prandial Glucose by Dr. Jaime Davidson * Clinical Implementation of the IDF Guidelines by Dr. Gerald Bernstein * New Routes of Delivery for Prandial Insulin by Dr. Jaime Guevarra * Controlling Side Effects of Tight Glycemic Control by Dr. Manon Khazrai
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at www.generex.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase'' of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.